中国P站

Intestinal barrier; Gut microbiota; Chemokines; Inflammatory Bowel Disease; Immune response; Dysbiosis; Diet; Inflammation; Epithelial cells; Signaling pathways

Introduction

The interplay between dietary components and the gut mucosal barrier significantly influences chemokine production and downstream immune responses, presenting potential therapeutic targets for Inflammatory Bowel Disease (IBD) [1].

Epithelial cell-derived chemokines play a crucial role in shaping the mucosal immune response and are implicated in the pathogenesis of various gastrointestinal disorders [2].

The gut microbiota profoundly impacts intestinal barrier function and immune cell activation through specific signaling pathways, suggesting probiotic interventions to restore homeostasis [3].

Inflammasomes play a significant role in regulating intestinal inflammation and barrier dysfunction, offering insights into novel therapeutic strategies for IBD [4].

Dysbiosis compromises the intestinal epithelial barrier, leading to increased permeability and subsequent immune activation via chemokine release [5].

Specific metabolites produced by the gut microbiota modulate intestinal inflammation and barrier function through direct interaction with immune and epithelial cells [6].

Specific signaling pathways are essential for maintaining intestinal epithelial barrier integrity and regulating chemokine production, identifying therapeutic targets for IBD [7].

Understanding the complex interplay between the gut microbiota, intestinal barrier function, and immune system is vital for maintaining intestinal homeostasis and preventing disease [8].

Aryl Hydrocarbon Receptor (AhR) activation enhances intestinal barrier function and dampens inflammatory responses by modulating chemokine expression and immune cell activity [9].

Environmental factors, like diet and stress, disrupt the intestinal barrier, leading to inflammation and immune dysregulation through altered chemokine profiles [10].

Description

The intestinal barrier, a complex and dynamic structure, is critical for maintaining homeostasis within the gastrointestinal tract. Dietary components can significantly impact the integrity of this barrier, subsequently influencing chemokine production and immune responses [1].

This modulation presents opportunities for therapeutic intervention in Inflammatory Bowel Disease (IBD), where barrier dysfunction and dysregulated immune responses are hallmarks. Epithelial cell-derived chemokines are key players in shaping the mucosal immune response, and their involvement in various gastrointestinal disorders underscores their importance [2].

The gut microbiota plays a pivotal role in regulating intestinal barrier function and immune cell activation through specific signaling pathways [3]. Dysbiosis, an imbalance in the gut microbiota, can compromise the intestinal epithelial barrier, leading to increased permeability and subsequent immune activation via chemokine release [5]. Specific metabolites produced by commensal bacteria can also modulate intestinal inflammation and barrier function through direct interaction with immune and epithelial cells [6]. These interactions highlight the complex interplay between the gut microbiota, the intestinal barrier, and the immune system.

Inflammasomes also contribute to the regulation of intestinal inflammation and barrier dysfunction, offering potential targets for therapeutic strategies in IBD [4]. Furthermore, specific signaling pathways are essential for maintaining intestinal epithelial barrier integrity and regulating chemokine production, underscoring their relevance as therapeutic targets for IBD [7]. The aryl hydrocarbon receptor (AhR) is another critical factor, with its activation enhancing intestinal barrier function and dampening inflammatory responses by modulating chemokine expression and immune cell activity [9]. Environmental factors, such as diet and stress, can disrupt the intestinal barrier, leading to inflammation and immune dysregulation through altered chemokine profiles [10].

Conclusion

The integrity of the intestinal barrier is critical for maintaining gut homeostasis, and its dysfunction is implicated in various gastrointestinal disorders, particularly Inflammatory Bowel Disease (IBD). Dietary components can modulate the gut mucosal barrier, influencing chemokine production and downstream immune responses, thus highlighting potential therapeutic targets for IBD. Epithelial cell-derived chemokines play a vital role in shaping mucosal immunity, while the gut microbiota significantly impacts intestinal barrier function and immune cell activation through specific signaling pathways. Dysbiosis, or an imbalance in the gut microbiota, can compromise the intestinal epithelial barrier, leading to increased permeability and subsequent immune activation via chemokine release. Metabolites produced by commensal bacteria can also modulate intestinal inflammation and barrier function through direct interactions with immune and epithelial cells. Inflammasomes contribute to the regulation of intestinal inflammation and barrier dysfunction, offering further therapeutic avenues for IBD. The aryl hydrocarbon receptor (AhR) activation enhances intestinal barrier function and dampens inflammatory responses by modulating chemokine expression and immune cell activity. Additionally, environmental factors like diet and stress can disrupt the intestinal barrier, resulting in inflammation and immune dysregulation. Understanding the complex interplay between these factors—diet, microbiota, chemokines, inflammasomes, and environmental influences—is crucial for developing effective strategies to maintain intestinal homeostasis and prevent disease.

References

1. Sharmila G, Anirban C, Subhajit C (2023) .J Nutr Biochem 115:109287.

   , ,

2. Jerrold RT, Brian B, Adam O (2019) .Mucosal Immunol 12:322-333.

   , ,

3. Maria GdA, Sophie CG, Elodie P (2016) .Science 351:1299-1303.

   , ,

4. Mohamed HZ, Patrick V, Mathilde B (2010) .Cell 140:491-501.

   , ,

5. CAT, Jonathan S, Rafael V (2016) .Cell 167:1478-1493.e10.

   , ,

6. Nicholas A, Colin C, Xiaoting F (2013) .Nature 504:458-462.

   , ,

7. Tsuyoshi S, Hitoshi H, Caitlin JK (2011) .Dig Dis Sci 56:2141-2160.

   , ,

8. Kristin RG, Stephen PH (2009) .J Allergy Clin Immunol 124:3-20; quiz 21-22.

   , ,

9. Brigitta S, Marc V, Anne O (2014) .Nat Rev Immunol 14:403-414.

   , ,

10. Michael C (2019) .Nat Rev Gastroenterol Hepatol 16:624-639.

    , ,